Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Stakeholders

2. Research & Forecasting

• 2.1. Research Methodology
  • 2.1.1. Research Instruments
    • 2.1.1.1. Secondary Instrument
    • 2.1.1.2. Primary Instrument
  • 2.1.2. Research Approaches
    • 2.1.2.1. Bottom-up Approach
    • 2.1.2.2. Top-down Approach
  • 2.1.3. Research Reliability & Validity
  • 2.1.4. Research Assumptions
  • 2.1.5. Vendor Inclusion Criteria
• 2.2. Forecasting Methodology
  • 2.2.1. Methodology for Market Estimation & Forecasting
  • 2.2.2. Significance and Importance of the Market Estimation & Forecasting

3. Executive Summary

4. Premium Insight

• 4.1. Market Connectivity
• 4.2. Market Data Feed
• 4.3. Market Dynamics
  • 4.3.1. Drivers
    • 4.3.1.1. Increasing utilization of plasma products across the globe in both existing and expanded indications
    • 4.3.1.2. Improving access to plasma based therapies and increasing use of immunoglobulins in various therapeutic areas
    • 4.3.1.3. Rising Geriatric Population Across the Globe
    • 4.3.1.4. Increasing diagnosis of diseases that can be treated with plasma products
    • 4.3.1.5. Increase in plasma collection
  • 4.3.2. Restraints
    • 4.3.2.1. High cost and limited reimbursement
    • 4.3.2.2. Emergence of recombinant alternatives
  • 4.3.3. Opportunities
    • 4.3.3.1. Advance treatment options available for Hemophilia Patients
    • 4.3.3.2. Advancements in process development for improved formulations
    • 4.3.3.3. New products are currently in clinical trials
  • 4.3.4. Challenges
    • 4.3.4.1. Stringent Government Regulations
    • 4.3.4.2. Emerging human pathogens and challenges in continuously supplying safe products through effective removal or inactivation
    • 4.3.4.3. Maintaining strong global supply and manufacturing networks
• 4.4. Porter’s Five Forces Analysis
  • 4.4.1. Threat of New Entrants
  • 4.4.2. Threat of Substitutes
  • 4.4.3. Bargaining Power of Customers
  • 4.4.4. Bargaining Power of Suppliers
  • 4.4.5. Industry Rivalry
• 4.5. Fractionation capacities and geographical expansions
• 4.6. Fractionator-owned plasma collection centers
• 4.7. New indications for plasma products

5. Global Plasma Fractionation Market, by Product

• 5.1. Introduction
• 5.2. Albumin
• 5.3. Coagulation Factor Concentrates
  • 5.3.1. Factor IX
  • 5.3.2. Factor VIII
  • 5.3.3. Factor XIII
  • 5.3.4. Fibrinogen Concentrates
  • 5.3.5. Prothrombin Complex Concentrate
  • 5.3.6. Von Willebrand Factor
• 5.4. Immunoglobulin
  • 5.4.1. Intravenous Immunoglobulin (IVIG)
  • 5.4.2. Subcutaneous Immunoglobulin (SCIG)
• 5.5. Protease Inhibitors

6. Global Plasma Fractionation Market, by Application

• 6.1. Introduction
• 6.2. Critical Care
• 6.3. Hemato-Oncology
• 6.4. Hematology
• 6.5. Neurology
• 6.6. Pulmonology
• 6.7. Rheumatology

7. Global Plasma Fractionation Market, by End User

• 7.1. Introduction
• 7.2. Academic & Research Institutes
• 7.3. Clinical Research Laboratories
• 7.4. Infectious Diseases

8. Global Plasma Fractionation Market, by Geography

• 8.1. Introduction
• 8.2. Americas Plasma Fractionation Market
  • 8.2.1. Americas Plasma Fractionation Market, by Country
    • 8.2.1.1. United States
    • 8.2.1.2. Brazil
    • 8.2.1.3. Canada
    • 8.2.1.4. Mexico
    • 8.2.1.5. Argentina
  • 8.2.2. Americas Plasma Fractionation Market, by Product
  • 8.2.3. Americas Plasma Fractionation Market, by Application
  • 8.2.4. Americas Plasma Fractionation Market, by End User
• 8.3. Europe, Middle East & Africa Plasma Fractionation Market
  • 8.3.1. Europe, Middle East & Africa Plasma Fractionation Market, by Country
    • 8.3.1.1. United Kingdom
    • 8.3.1.2. Germany
    • 8.3.1.3. France
    • 8.3.1.4. Saudi Arabia
    • 8.3.1.5. United Arab Emirates
    • 8.3.1.6. Italy
    • 8.3.1.7. Russia
  • 8.3.2. Europe, Middle East & Africa Plasma Fractionation Market, by Product
  • 8.3.3. Europe, Middle East & Africa Plasma Fractionation Market, by Application
  • 8.3.4. Europe, Middle East & Africa Plasma Fractionation Market, by End User
• 8.4. Asia-Pacific Plasma Fractionation Market
  • 8.4.1. Asia-Pacific Plasma Fractionation Market, by Country
    • 8.4.1.1. China
    • 8.4.1.2. Japan
    • 8.4.1.3. India
    • 8.4.1.4. Australia
  • 8.4.2. Asia-Pacific Plasma Fractionation Market, by Product
  • 8.4.3. Asia-Pacific Plasma Fractionation Market, by Application
  • 8.4.4. Asia-Pacific Plasma Fractionation Market, by End User

9. Competitive Strategic Window

• 9.1. Introduction
  • 9.1.1. Leverage Zone
  • 9.1.2. Vantage Zone
  • 9.1.3. Speculative Zone
  • 9.1.4. Bottleneck Zone

10. Competitive News Feed Analysis

11. Company Usability Profiles

• 11.1. Baxalta Incorporated
• 11.2. Bio Products Laboratory Ltd.
• 11.3. Biotest Aktiengesellschaft
• 11.4. CSL Limited
• 11.5. China Biologic Products Holdings, Inc.
• 11.6. Green Cross Corporation
• 11.7. Grifols, S.A.
• 11.8. Japan Blood Products Organization
• 11.9. Kedrion S.p.A.
• 11.10. LFB S.A.
• 11.11. Octapharma AG
• 11.12. Sanquin Blood Supply Foundation
• 11.13. Shanghai RAAS Blood Products Co., Ltd.
• 11.14. Shire PLC

12. Appendix

• 12.1. Top Reports
• 12.2. Author Details

LIST OF TABLES (30 TABLES)

TABLE 1. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 2. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2016 - 2024 (USD MILLION)

TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 19. AMERICAS PLASMA FRACTIONATION MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 20. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 21. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2016 - 2024 (USD MILLION)

TABLE 22. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 23. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 24. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 25. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2016 - 2024 (USD MILLION)

TABLE 26. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 27. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 28. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 29. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2016 - 2024 (USD MILLION)

TABLE 30. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

LIST OF FIGURES (32 TABLES)

FIGURE 1. GLOBAL PLASMA FRACTIONATION MARKET: YEARS CONSIDERED FOR THE STUDY

FIGURE 2. GLOBAL PLASMA FRACTIONATION MARKET: KEY RESEARCH METHODOLOGY

FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET: KEY RESEARCH INSTRUMENTS

FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET: KEY SECONDARY INSTRUMENT SOURCES

FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET: KEY POTENTIAL RESPONDENTS

FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT

FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET: KEY RESEARCH APPROACHES

FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET: KEY DATA TRIANGULATION

FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET: KEY RESEARCH ASSUMPTIONS

FIGURE 10. PLASMA FRACTIONATION MARKET: KEY MARKET CONNECTIVITY

FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2016 - 2024 (USD MILLION)

FIGURE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)

FIGURE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2017 VS 2024 (USD MILLION)

FIGURE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)

FIGURE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GEOGRAPHY, 2017 (USD MILLION)

FIGURE 29. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024

FIGURE 30. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024

FIGURE 31. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2024

FIGURE 32. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PLASMA FRACTIONATION MARKET, BY GEOGRAPHY, 2024

The global plasma fractionation market is expected to grow from USD 17,921.67 million 2017 to USD 27,782.67 million by the end of 2024 at a Compound Annual Growth Rate (CAGR) of 6.46%.

“Increasing utilization of plasma products across the globe in both existing and expanded indicationsis one of the factors largely attributing to the growth of plasma fractionation market globally”

The factors attributing to the growth of the market are increasing utilization of plasma products across the globe in both existing and expanded indications, improving access to plasma based therapies and increasing use of immunoglobulins in various therapeutic areas, rising geriatric population across the globe, increasing diagnosis of diseases that can be treated with plasma products, and increase in plasma collection. However, some factors such as high cost and limited reimbursement, and emergence of recombinant alternatives may hinder the market growth. The global plasma fractionation market is expected to showcase the opportunities such as advance treatment options available for hemophilia patients, advancements in process development for improved formulations, and new products are currently in clinical trials. In the near future, the market may face the possible challenges in the growth due to stringent government regulations, emerging human pathogens and challenges in continuously supplying safe products through effective removal or inactivation, and maintaining strong global supply and manufacturing networks. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the global plasma fractionation market market.

On the basis of product, the global plasma fractionation market is studied across Albumin, Coagulation Factor Concentrates, Immunoglobulin, and Protease Inhibitors.

On the basis of application, the global plasma fractionation market is studied across Critical Care, Hemato-Oncology, Hematology, Neurology, Pulmonology, and Rheumatology.

On the basis of end user, the global plasma fractionation market is studied across Academic & Research Institutes, Clinical Research Laboratories, and Infectious Diseases.

On the basis of geography, the global plasma fractionation market is studied across Americas, (United States, Brazil, Canada, Mexico, and Argentina) Europe, Middle East & Africa, (United Kingdom, Germany, France, Saudi Arabia, United Arab Emirates, Italy, and Russia) and Asia-Pacific (China, Japan, India, and Australia).

“Baxalta Incorporated: The potential growing player for the global plasma fractionation market”

The key players profiled in the global plasma fractionation market are Baxalta Incorporated, Bio Products Laboratory Ltd., Biotest Aktiengesellschaft, CSL Limited, China Biologic Products Holdings, Inc., Green Cross Corporation, Grifols, S.A., Japan Blood Products Organization, Kedrion S.p.A., LFB S.A., Octapharma AG, Sanquin Blood Supply Foundation, Shanghai RAAS Blood Products Co., Ltd., and Shire PLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the global plasma fractionation market.
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the global plasma fractionation market.
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the global plasma fractionation market.
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the global plasma fractionation market.
5. Competitive Assessment & Intelligence: Provides exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market.